Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT [Yahoo! Finance]
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Opus Genetics (NASDAQ:IRD) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.